Bristol Myers Squibb stock edges lower as Sotyktu data and ORM-6151 halt shape investor focus

Published on 09/18/2026 at 12:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bristol Myers Squibb stock closed at USD 62.84 on the NYSE on September 17, 2026, about 8.4 percent below its 52-week high of USD 68.64. New two-year Sotyktu data and the halt of ORM-6151 development are now central to how investors weigh the shares.

BMY, US1101221083, Illustration mit AI erstellt.

Bristol Myers Squibb Company stock (ISIN US1101221083) closed at USD 62.84 on the New York Stock Exchange on September 17, 2026, down 1.19% from the previous session, leaving the shares about 8.4% below their 52-week high of USD 68.64 as investors digest fresh immunology trial results and a pipeline setback.

Sotyktu data underpin immunology narrative

On September 17, 2026, Bristol Myers Squibb announced positive results through two years of treatment from the Phase 3 POETYK PsA-2 study, including its open-label extension, showing durable efficacy and a consistent safety profile for Sotyktu (deucravacitinib) in adults with active psoriatic arthritis, according to Business Wire.

Additional detail on the POETYK PsA-2 trial shows that in the open-label extension through Week 104, patients continuously treated with Sotyktu achieved American College of Rheumatology (ACR) 20, 50 and 70 response rates of 76.2%, 52.6% and 34.6%, respectively, reinforcing the drug's long-term efficacy in psoriatic arthritis, according to GuruFocus.

For investors, the combination of a durable efficacy profile and consistent safety over two years strengthens Bristol Myers Squibb's immunology portfolio at a time when differentiated, long-term data can support pricing power and competitive positioning against other targeted therapies in inflammatory diseases.

ORM-6151 halt highlights pipeline risk

Alongside the positive Sotyktu data, Bristol Myers Squibb has decided to halt development of ORM-6151, a blood cancer degrader-antibody conjugate candidate that had been licensed from Orum Therapeutics, following a review of Phase 1 clinical data conducted in the United States, Europe and Canada, as reported by Chosun Biz on September 18, 2026.

The halt means that Orum Therapeutics will not receive up to USD 80 million in potential milestone payments tied to ORM-6151, although it retains the USD 100 million upfront payment it had already received under the 2023 asset transfer agreement, according to Aju Press.

For Bristol Myers Squibb shareholders, the decision underscores the inherent clinical risk in early-stage oncology assets but is mitigated by the fact that the company can reallocate research and development resources from ORM-6151 toward other hematology and oncology programs, while its financial exposure to the halted project remains limited relative to its broader pipeline.

Price, valuation and dividend context

Market data from the New York Stock Exchange show that Bristol Myers Squibb shares closed at USD 62.84 on September 17, 2026, with a loss of 0.76 dollars or 1.19 percent on the day, while after-hours trading indicated a price of USD 62.90, up 0.06 dollars or 0.10 percent, according to CNBC.

A quote overview shows that, as of September 18, 2026, Bristol Myers Squibb has a 52-week trading range between USD 42.53 and USD 68.64 and a market capitalization of approximately USD 129.46 billion, according to Morningstar, placing the current price roughly USD 20.31, or about 47.8 percent, above the 52-week low but still USD 5.80, or about 8.4 percent, below the 52-week high.

An analysis on valuation and income notes that investor focus has increasingly turned to Bristol Myers Squibb's dividend sustainability and relative valuation, with the shares recently assessed as trading about 12.4 percent above an intrinsic value estimate using the GF Value framework, according to GuruFocus.

Analyst and investor perspective

Within this environment, recent commentary has highlighted that Bristol Myers Squibb's combination of a reinforced immunology franchise, evidenced by the two-year Sotyktu Psoriatic Arthritis data, and a steady dividend stream provides a support factor for the stock, even as clinical risk from discontinued programs such as ORM-6151 weighs on sentiment in specific segments of the pipeline.

For retail investors, the quantified picture is mixed: on the one hand, the share price's 44.42 percent 12-month total return and year-to-date gain of 17.55 percent reported in a performance overview reflect strong momentum over the past year, while on the other hand, trading modestly above some fair value estimates suggests that further upside may increasingly depend on the successful execution of the broader late-stage pipeline and clarity on long-term cash flow coverage of the dividend, as discussed by Yahoo Finance on September 18, 2026.

Bristol Myers Squibb stock price snapshot

As of the close on September 17, 2026, Bristol Myers Squibb stock stood at USD 62.84 on the New York Stock Exchange, with after-hours indications at USD 62.90, and the shares trading between USD 42.53 and USD 68.64 over the past 52 weeks and supported by a market capitalization of about USD 129.46 billion.